18th ICML
Bispecific antibody bridging before CAR T-cell therapy appears safe and effective in LBCL, study shows.
AI model predicted 12-month CAR T-cell outcomes in R/R LBCL using pretreatment images with 77% sensitivity.
M-Pola more than doubled PFS and boosted response rates vs. R-GemOx in transplant-ineligible R/R LBCL patients.
C5 DLBCL patients saw better outcomes with Pola-R-CHP vs R-CHOP, per POLARIX trial subgroup analysis.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.